Yahoo Web Search

Search results

1. • 

     Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief

     Verywell Health via Yahoo News· 16 hours ago

     But after two pregnancies and the emergence of two new autoimmune conditions, my psoriasis became...

2. • 

     Nail Psoriasis

     Health via Yahoo News· 5 days ago

     What Causes Nail Psoriasis? Most people with nail psoriasis have psoriatic inflammation, such as plaque psoriasis ...

3. • Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. -...

     Benzinga· 1 day ago

     "We are proud to make SIMLANDI available in the U.S. to patients and providers," said Thomas Rainey, Senior ...

4. • 

     J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial

     Clinical Trials Arena via Yahoo Finance· 23 hours ago

     DC from 19 to 21 May. J&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23...

5. • Alvotech (ALVO) Scheduled to Post Quarterly Earnings on Tuesday

     ETF DAILY NEWS· 3 days ago

     Alvotech (NYSE:ALVO – Get Free Report) will post its quarterly earnings results after the market closes on Tuesday, May 21st. Individual interested in participating in the company’s earnings ...

6. • Amgen Inc. (NASDAQ:AMGN) Holdings Cut by Panagora Asset Management Inc.

     ETF DAILY NEWS· 2 days ago

     Panagora Asset Management Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure ...

7. • AltruBio, after tweaking checkpoint drug, raises $225M for midphase ulcerative colitis program

     FierceBiotech· 22 hours ago

     AltruBio has roared back after another pivot in its twisty history, securing up to $225 million in series B funding to take an immune checkpoint enhancer through a midphase ulcerative colitis ...

8. • AbbVie Inc. (NYSE:ABBV) to Post Q2 2024 Earnings of $3.01 Per Share, Zacks Research Forecasts

     ETF DAILY NEWS· 6 days ago

     AbbVie Inc. (NYSE:ABBV – Free Report) – Analysts at Zacks Research lifted their Q2 2024 earnings estimates for shares of AbbVie in a research report issued to clients and investors on Tuesday ...

9. • TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...

     FOX 23 News Albany· 2 days ago

     WASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...

10. • AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...

      WKBN 27 Youngstown· 5 days ago

      - AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory ...